PharmAthene Inc

Find Ratings Reports
PIP : AMEX : Health Care
$3.3 | %
Today's Range: 3.15 - 3.3
Avg. Daily Volume: 950000.0
01/20/17 - 4:01 PM ET

Financial Analysis


PHARMATHENE INC's gross profit margin for the third quarter of its fiscal year 2016 has significantly decreased when compared to the same period a year ago. Even though sales decreased, the net income has increased, representing an increase to the bottom line. PHARMATHENE INC is extremely liquid. Currently, the Quick Ratio is 36.89 which clearly shows the ability to cover any short-term cash needs. PIP managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.

At the same time, stockholders' equity ("net worth") has greatly increased by 671.74% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q3 FY16 Q3 FY15
Net Sales ($mil)0.991.16
EBITDA ($mil)-3.96-1.2
EBIT ($mil)-3.99-1.24
Net Income ($mil)109.24-1.32


Balance Sheet Q3 FY16 Q3 FY15
Cash & Equiv. ($mil)135.9517.39
Total Assets ($mil)140.5420.9
Total Debt ($mil)0.00.0
Equity ($mil)136.3817.67


Profitability Q3 FY16 Q3 FY15
Gross Profit Margin-398.19-103.98
EBITDA Margin-398.18-103.97
Operating Margin-401.41-107.01
Sales Turnover0.040.54
Return on Assets81.69-23.11
Return on Equity84.18-27.33
Debt Q3 FY16 Q3 FY15
Current Ratio37.037.66
Debt/Capital0.00.0
Interest Expense0.00.01
Interest Coverage0.0-137.44


Share Data Q3 FY16 Q3 FY15
Shares outstanding (mil)66.4264.36
Div / share0.00.0
EPS1.67-0.02
Book value / share2.050.27
Institutional Own % n/a n/a
Avg Daily Volume934385.0155884.0

Valuation


BUY. PHARMATHENE INC's P/E ratio indicates a significant discount compared to an average of 33.71 for the Biotechnology industry and a significant discount compared to the S&P 500 average of 25.41. To use another comparison, its price-to-book ratio of 1.53 indicates a discount versus the S&P 500 average of 2.83 and a significant discount versus the industry average of 11.23. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. Upon assessment of these and other key valuation criteria, PHARMATHENE INC proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
PIP 1.80 Peers 33.71   PIP 1.79 Peers 26.76

Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.

PIP is trading at a significant discount to its peers.

 

Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

PIP is trading at a significant discount to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
PIP NA Peers 24.59   PIP NA Peers 0.40

Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.

Ratio not available.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
PIP 1.53 Peers 11.23   PIP 2287.50 Peers 4.03

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

PIP is trading at a significant discount to its peers.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

PIP is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
PIP 38.89 Peers 131.67   PIP -51.99 Peers 548.88

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

PIP is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

PIP significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades